Y C Gary Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2411905/publications.pdf

Version: 2024-02-01

239 papers	10,665 citations	31974 53 h-index	37202 96 g-index

240 all docs	240 docs citations	240 times ranked	5830 citing authors

#	Article	IF	Citations
1	Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. New England Journal of Medicine, 2011, 365, 518-526.	27.0	624
2	Investigation of a unilateral pleural effusion in adults: British Thoracic Society pleural disease guideline 2010. Thorax, 2010, 65, ii4-ii17.	5.6	578
3	Effect of an Indwelling Pleural Catheter vs Chest Tube and Talc Pleurodesis for Relieving Dyspnea in Patients With Malignant Pleural Effusion. JAMA - Journal of the American Medical Association, 2012, 307, 2383.	7.4	508
4	Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score. Thorax, 2014, 69, 1098-1104.	5.6	324
5	Ultrasound-Guided Thoracentesis*. Chest, 2003, 123, 418-423.	0.8	302
6	Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 839-849.	5.6	284
7	CD56bright NK Cells Are Enriched at Inflammatory Sites and Can Engage with Monocytes in a Reciprocal Program of Activation. Journal of Immunology, 2004, 173, 6418-6426.	0.8	263
8	Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. Journal of Clinical Investigation, 2009, 119, 2550-63.	8.2	251
9	Randomized Trials Describing Lung Inflammation after Pleurodesis with Talc of Varying Particle Size. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 377-382.	5.6	231
10	Effect of an Indwelling Pleural Catheter vs Talc Pleurodesis on Hospitalization Days in Patients With Malignant Pleural Effusion. JAMA - Journal of the American Medical Association, 2017, 318, 1903.	7.4	192
11	Outpatient Talc Administration by Indwelling Pleural Catheter for Malignant Effusion. New England Journal of Medicine, 2018, 378, 1313-1322.	27.0	183
12	Pleurodesis Practice for Malignant Pleural Effusions in Five English-Speaking Countries. Chest, 2003, 124, 2229-2238.	0.8	172
13	Conservative versus Interventional Treatment for Spontaneous Pneumothorax. New England Journal of Medicine, 2020, 382, 405-415.	27.0	164
14	Effect of Opioids vs NSAIDs and Larger vs Smaller Chest Tube Size on Pain Control and Pleurodesis Efficacy Among Patients With Malignant Pleural Effusion. JAMA - Journal of the American Medical Association, 2015, 314, 2641.	7.4	155
15	Clinical Outcomes of Indwelling Pleural Catheter-Related Pleural Infections. Chest, 2013, 144, 1597-1602.	0.8	150
16	Indwelling Pleural Catheters Reduce Inpatient Days Over Pleurodesis for Malignant Pleural Effusion. Chest, 2012, 142, 394-400.	0.8	140
17	Aggressive versus symptom-guided drainage of malignant pleural effusion via indwelling pleural catheters (AMPLE-2): an open-label randomised trial. Lancet Respiratory Medicine,the, 2018, 6, 671-680.	10.7	138
18	Prophylactic radiotherapy for the prevention of procedure-tract metastases after surgical and large-bore pleural procedures in malignant pleural mesothelioma (SMART): a multicentre, open-label, phase 3, randomised controlled trial. Lancet Oncology, The, 2016, 17, 1094-1104.	10.7	137

#	Article	IF	Citations
19	Pleural Tuberculosis in the United States. Chest, 2007, 131, 1125-1132.	0.8	136
20	Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma. Thorax, 2014, 69, 895-902.	5.6	128
21	Blood culture bottle culture of pleural fluid in pleural infection. Thorax, 2011, 66, 658-662.	5.6	127
22	Vascular endothelial growth factor: the key mediator in pleural effusion formation. Current Opinion in Pulmonary Medicine, 2002, 8, 294-301.	2.6	124
23	Asbestosis and Idiopathic Pulmonary Fibrosis: Comparison of Thin-Section CT Features. Radiology, 2003, 229, 731-736.	7.3	124
24	Adenosine Deaminase Levels in Nontuberculous Lymphocytic Pleural Effusions. Chest, 2001, 120, 356-361.	0.8	121
25	Intrapleural Tissue Plasminogen Activator and Deoxyribonuclease for Pleural Infection. An Effective and Safe Alternative to Surgery. Annals of the American Thoracic Society, 2014, 11, 1419-1425.	3.2	113
26	Spontaneous pneumothorax: time to rethink management?. Lancet Respiratory Medicine,the, 2015, 3, 578-588.	10.7	103
27	Outcome of patients with nonspecific pleuritis/fibrosis on thoracoscopic pleural biopsies. European Journal of Cardio-thoracic Surgery, 2010, 38, 472-477.	1.4	100
28	Postmortem Findings of Malignant Pleural Mesothelioma. Chest, 2012, 142, 1267-1273.	0.8	99
29	Management of malignant pleural effusions. Respirology, 2004, 9, 148-156.	2.3	98
30	Prevalence and Clinical Course of Pleural Effusions at 30 Days after Coronary Artery and Cardiac Surgery. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 1567-1571.	5.6	94
31	Clinically Important Factors Influencing the Diagnostic Measurement of Pleural Fluid pH and Glucose. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 483-490.	5.6	94
32	Clinical Impact and Reliability of Pleural Fluid Mesothelin in Undiagnosed Pleural Effusions. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 437-444.	5.6	93
33	Transforming Growth Factor Î² Induces Vascular Endothelial Growth Factor Elaboration from Pleural Mesothelial Cellsin Vivoandin Vitro. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 88-94.	5.6	89
34	Complications of indwelling pleural catheter use and their management. BMJ Open Respiratory Research, 2016, 3, e000123.	3.0	89
35	Risk reduction in pleural procedures: sonography, simulation and supervision. Current Opinion in Pulmonary Medicine, 2010, 16, 340-350.	2.6	78
36	Empyema thoracis: new insights into an old disease. European Respiratory Review, 2010, 19, 220-228.	7.1	78

#	Article	IF	Citations
37	Catheter-Tract Metastases Associated With Chronic Indwelling Pleural Catheters. Chest, 2007, 131, 1232-1234.	0.8	77
38	Physiology of breathlessness associated with pleural effusions. Current Opinion in Pulmonary Medicine, 2015, 21, 338-345.	2.6	75
39	Dose De-escalation of Intrapleural Tissue Plasminogen Activator Therapy for Pleural Infection. The Alteplase Dose Assessment for Pleural Infection Therapy Project. Annals of the American Thoracic Society, 2017, 14, 929-936.	3.2	74
40	Transforming Growth Factor- Î²2Induces Pleurodesis Significantly Faster than Talc. American Journal of Respiratory and Critical Care Medicine, 2001, 163, 640-644.	5.6	68
41	Vascular Endothelial Growth Factor Level Correlates With Transforming Growth Factor-Î² Isoform Levels in Pleural Effusions. Chest, 2000, 118, 1747-1753.	0.8	66
42	Biomarkers for mesothelioma. Current Opinion in Pulmonary Medicine, 2007, 13, 339-343.	2.6	66
43	Diagnostic accuracy, safety and utilisation of respiratory physician-delivered thoracic ultrasound. Thorax, 2010, 65, 449-453.	5.6	66
44	Pleural infection: Changing bacteriology and its implications. Respirology, 2011, 16, 598-603.	2.3	66
45	Management of malignant pleural mesothelioma: a critical review. Current Opinion in Pulmonary Medicine, 2000, 6, 267-274.	2.6	62
46	Intrapleural Fibrinolysis for the Treatment of Indwelling Pleural Catheter-Related Symptomatic Loculations. Chest, 2015, 148, 746-751.	0.8	62
47	Diagnostic molecular biomarkers for malignant pleural effusions. Future Oncology, 2011, 7, 737-752.	2.4	61
48	Symptomatic Persistent Post-Coronary Artery Bypass Graft Pleural Effusions Requiring Operative Treatment. Chest, 2001, 119, 795-800.	0.8	60
49	Management of malignant pleural effusions. Current Opinion in Pulmonary Medicine, 2013, 19, 374-379.	2.6	58
50	Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma. Thorax, 2014, 69, 638-647.	5.6	58
51	Benign asbestos pleural diseases. Current Opinion in Pulmonary Medicine, 2003, 9, 266-271.	2.6	57
52	Interventional therapies for malignant pleural effusions: The present and the future. Respirology, 2014, 19, 809-822.	2.3	57
53	Pleural Effusions at First ED Encounter Predict Worse Clinical Outcomes in PatientsÂWith Pneumonia. Chest, 2016, 149, 1509-1515.	0.8	57
54	Catheter Tract Metastasis Associated With Indwelling Pleural Catheters. Chest, 2014, 146, 557-562.	0.8	56

#	Article	IF	Citations
55	Setting up a specialist pleural disease service. Respirology, 2010, 15, 1028-1036.	2.3	55
56	Intrapleural tissue plasminogen activator and deoxyribonuclease therapy for pleural infection. Journal of Thoracic Disease, 2015, 7, 999-1008.	1.4	55
57	Pseudochylothorax Without Pleural Thickening. Chest, 2009, 136, 1144-1147.	0.8	54
58	The many faces of transforming growth factor-Î² in pleural diseases. Current Opinion in Pulmonary Medicine, 2001, 7, 173-179.	2.6	52
59	Pleural Space as a Site of Ectopic Gene Delivery. Chest, 2003, 123, 202-208.	0.8	50
60	Pleurodesis outcome in malignant pleural mesothelioma: TableÂ1. Thorax, 2013, 68, 594-596.	5.6	50
61	Prophylactic radiotherapy for pleural puncture sites in mesothelioma: the controversy continues. Current Opinion in Pulmonary Medicine, 2008, 14, 326-330.	2.6	48
62	Interferon-gamma release assays for the diagnosis of TB pleural effusions: hype or real hope?. Current Opinion in Pulmonary Medicine, 2009, 15, 358-365.	2.6	48
63	Fractured Indwelling Pleural Catheters. Chest, 2012, 141, 1090-1094.	0.8	47
64	Pleuroscopic cryoprobe biopsies of the pleura: A feasibility and safety study. Respirology, 2015, 20, 327-332.	2.3	47
65	Randomized Controlled Trial of Urokinase versus Placebo for Nondraining Malignant Pleural Effusion. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 502-508.	5.6	47
66	Transforming growth factor beta 2 (TGFbeta 2) produces effective pleurodesis in sheep with no systemic complications. Thorax, 2000, 55, 1058-1062.	5.6	45
67	Contemporary best practice in the management of malignant pleural effusion. Therapeutic Advances in Respiratory Disease, 2018, 12, 175346661878509.	2.6	45
68	Loss of miR-223 and JNK Signaling Contribute to Elevated Stathmin in Malignant Pleural Mesothelioma. Molecular Cancer Research, 2015, 13, 1106-1118.	3.4	44
69	Variations in Pleural Fluid WBC Count and Differential Counts With Different Sample Containers and Different Methods. Chest, 2003, 123, 1181-1187.	0.8	43
70	Management of Malignant Pleural Mesothelioma. Clinics in Chest Medicine, 2006, 27, 335-354.	2.1	43
71	Optimal Chest Drain Size: The Rise of the Small-Bore Pleural Catheter. Seminars in Respiratory and Critical Care Medicine, 2010, 31, 760-768.	2.1	43
72	Transforming growth factor-Â induces collagen synthesis without inducing IL-8 production in mesothelial cells. European Respiratory Journal, 2003, 22, 197-202.	6.7	42

#	Article	IF	Citations
73	Current Controversies in the Management of Malignant Pleural Effusions. Seminars in Respiratory and Critical Care Medicine, 2014, 35, 723-731.	2.1	42
74	The Pleural Effusion And Symptom Evaluation (PLEASE) study of breathlessness in patients with a symptomatic pleural effusion. European Respiratory Journal, 2020, 55, 1900980.	6.7	40
75	Tissue Plasminogen Activator Potently Stimulates Pleural Effusion via a Monocyte Chemotactic Protein-1â€“Dependent Mechanism. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 105-112.	2.9	39
76	Respiratory Chest Pain: Diagnosis and Treatment. Medical Clinics of North America, 2010, 94, 217-232.	2.5	38
77	Characterization of a New Mouse Model of Empyema and the Mechanisms of Pleural Invasion by Streptococcus pneumoniae. American Journal of Respiratory Cell and Molecular Biology, 2012, 46, 180-187.	2.9	38
78	Asbestos-induced and Smoking-related Disease: Apportioning Pulmonary Function Deficit by Using Thin-Section CT. Radiology, 2007, 242, 258-266.	7.3	35
79	Predictors of Clinical Use of Pleurodesis and/or Indwelling Pleural Catheter Therapy for Malignant Pleural Effusion. Chest, 2015, 147, 1629-1634.	0.8	35
80	Thoracic ultrasound recognition of competence: A position paper of the Thoracic Society of Australia and New Zealand. Respirology, 2017, 22, 405-408.	2.3	34
81	Pleurodesis for malignant pleural effusions: current controversies and variations in practices. Current Opinion in Pulmonary Medicine, 2004, 10, 305-310.	2.6	33
82	Indwelling Pleural Catheter: Changing the Paradigm of Malignant Effusion Management. Journal of Thoracic Oncology, 2011, 6, 655-657.	1.1	33
83	Medical thoracoscopy. Current Opinion in Pulmonary Medicine, 2014, 20, 358-365.	2.6	33
84	Pleural effusion in patients with pulmonary embolism. Respirology, 2008, 13, 832-836.	2.3	31
85	Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncology, The, 2008, 9, 946-952.	10.7	31
86	Causes and Management of Common Benign Pleural Effusions. Thoracic Surgery Clinics, 2013, 23, 25-42.	1.0	31
87	Study protocol for a randomised controlled trial of invasive versus conservative management of primary spontaneous pneumothorax. BMJ Open, 2016, 6, e011826.	1.9	31
88	Bacteriology and clinical outcomes of patients with cultureâ€positive pleural infection in Western Australia: A 6â€year analysis. Respirology, 2019, 24, 171-178.	2.3	31
89	Fibrin turnover and pleural organization: bench to bedside. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2018, 314, L757-L768.	2.9	30
90	Comparing approaches to the management of malignant pleural effusions. Expert Review of Respiratory Medicine, 2017, 11, 273-284.	2.5	29

#	Article	IF	Citations
91	Comparing transforming growth factor-beta2, talc and bleomycin as pleurodesing agents in sheep. Respirology, 2002, 7, 209-216.	2.3	28
92	Ongoing Search for Effective Intrapleural Therapy for Empyema. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1-2.	5.6	28
93	Surgical resection of mesothelioma: an evidence-free practice. Lancet, The, 2014, 384, 1080-1081.	13.7	28
94	Characterization of hypoxia in malignant pleural mesothelioma with FMISO PET-CT. Lung Cancer, 2015, 90, 55-60.	2.0	28
95	Spontaneous pneumothorax in diffuse cystic lung diseases. Current Opinion in Pulmonary Medicine, 2017, 23, 323-333.	2.6	27
96	Malignant pleural fluid from mesothelioma has potent biological activities. Respirology, 2017, 22, 192-199.	2.3	27
97	AABIP Evidence-informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 229-245.	1.4	27
98	Ability of Procalcitonin to Discriminate Infection from Non-Infective Inflammation Using Two Pleural Disease Settings. PLoS ONE, 2012, 7, e49894.	2.5	26
99	Radiographic (ILO) readings predict arterial oxygen desaturation during exercise in subjects with asbestosis. Occupational and Environmental Medicine, 2003, 60, 201-206.	2.8	25
100	Longitudinal Measurement of Pleural Fluid Biochemistry and Cytokines in Malignant Pleural Effusions. Chest, 2016, 149, 1494-1500.	0.8	25
101	Management of Indwelling Tunneled Pleural Catheters. Chest, 2020, 158, 2221-2228.	0.8	25
102	Pleurodesis for malignant pleural effusion: talc, toxicity and where next?. Thorax, 2008, 63, 572-574.	5.6	24
103	Pleural infection. Current Opinion in Pulmonary Medicine, 2012, 18, 321-325.	2.6	24
104	Growth factors in pleural fibrosis. Current Opinion in Pulmonary Medicine, 2006, 12, 251-258.	2.6	23
105	The diminishing role of surgery in pleural disease. Current Opinion in Pulmonary Medicine, 2011, 17, 247-254.	2.6	23
106	BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study. Journal of Thoracic Oncology, 2022, 17, 921-930.	1.1	23
107	Feasibility of objectively measured physical activity and sedentary behavior in patients with malignant pleural effusion. Supportive Care in Cancer, 2017, 25, 3133-3141.	2.2	22
108	Protocol of the Australasian Malignant Pleural Effusion (AMPLE) trial: a multicentre randomised study comparing indwelling pleural catheter versus talc pleurodesis. BMJ Open, 2014, 4, e006757.	1.9	21

#	Article	IF	Citations
109	A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma. Lung Cancer, 2020, 140, 87-92.	2.0	21
110	Use of cytokeratin fragments 19.1 and 19.21 (Cyfra 21â€1) in the differentiation of malignant and benign pleural effusions. Australian and New Zealand Journal of Medicine, 1999, 29, 765-769.	0.5	20
111	Lymphocytes in pleural disease. Current Opinion in Pulmonary Medicine, 2005, 11, 334-339.	2.6	20
112	Pleural disease: A forgotten frontier in respiratory research. Respirology, 2006, 11, 4-5.	2.3	20
113	Surgical and non-surgical management of malignant pleural effusions. Expert Review of Respiratory Medicine, 2018, 12, 15-26.	2.5	20
114	MicroRNA Signatures in Malignant Pleural Mesothelioma Effusions. Disease Markers, 2019, 2019, 1-9.	1.3	20
115	Phase I trial of the single-chain urokinase intrapleural LTI-01 in complicated parapneumonic effusions or empyema. JCI Insight, 2019, 4, .	5.0	20
116	Pleural Fluid Levels of Interleukin-5 and Eosinophils Are Closely Correlated. Chest, 2002, 122, 576-580.	0.8	19
117	Translational Research in Pleural Infection and Beyond. Chest, 2016, 150, 1361-1370.	0.8	19
118	Human pleural fluid is a potent growth medium for Streptococcus pneumoniae. PLoS ONE, 2017, 12, e0188833.	2.5	17
119	Protocol of the Australasian Malignant Pleural Effusion-2 (AMPLE-2) trial: a multicentre randomised study of aggressive versus symptom-guided drainage via indwelling pleural catheters. BMJ Open, 2016, 6, e011480.	1.9	16
120	Pseudochylothorax, an Unknown Disease: Response. Chest, 2010, 137, 1005.	0.8	15
121	Protocol for the surgical and large bore procedures in malignant pleural mesothelioma and radiotherapy trial (SMART Trial): an RCT evaluating whether prophylactic radiotherapy reduces the incidence of procedure tract metastases. BMJ Open, 2015, 5, e006673-e006673.	1.9	15
122	Protocol of the PLeural Effusion And Symptom Evaluation (PLEASE) study on the pathophysiology of breathlessness in patients with symptomatic pleural effusions. BMJ Open, 2016, 6, e013213.	1.9	15
123	Relationship of pleural fluid pH and glucose: a multi-centre study of 2,971 cases. Journal of Thoracic Disease, 2019, 11, 123-130.	1.4	15
124	Activation of proteinase-activated receptor-2 in mesothelial cells induces pleural inflammation. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 288, L734-L740.	2.9	14
125	Diagnosing Pleural Effusion. Chest, 2007, 131, 942-943.	0.8	14
126	Role of <scp>MCP</scp>â€1 in pleural effusion development in a carrageenanâ€induced murine model of pleurisy. Respirology, 2017, 22, 758-763.	2.3	14

#	Article	IF	Citations
127	Body composition and nutritional status in malignant pleural mesothelioma: implications for activity levels and quality of life. European Journal of Clinical Nutrition, 2019, 73, 1412-1421.	2.9	14
128	Breathlessness Predicts Survival in Patients With Malignant Pleural Effusions. Chest, 2021, 160, 351-357.	0.8	14
129	Pulmonary and meningeal cryptococcosis in pulmonary alveolar proteinosis. Australian and New Zealand Journal of Medicine, 1999, 29, 843-844.	0.5	13
130	A commercially available preparation of <scp>S</scp>taphylococcus aureus bioâ€products potently inhibits tumour growth in a murine model of mesothelioma. Respirology, 2014, 19, 1025-1033.	2.3	13
131	Phenotyping malignant pleural effusions. Current Opinion in Pulmonary Medicine, 2016, 22, 350-355.	2.6	13
132	Comparing transforming growth factor beta-2 and fibronectin as pleurodesing agents. Respirology, 2001, 6, 281-286.	2.3	12
133	Road ahead to respiratory health: Experts chart future research directions. Respirology, 2009, 14, 625-636.	2.3	12
134	Advantages of indwelling pleural catheters for management of malignant pleural effusions. Current Respiratory Care Reports, 2013, 2, 93-99.	0.6	12
135	Pneumothorax, Chylothorax, Hemothorax, and Fibrothorax. , 2016, , 1439-1460.e10.		12
136	Management of Malignant Pleural Effusionsâ€"What Is New. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 323-339.	2.1	12
137	Advances in pathological diagnosis of mesothelioma. Current Opinion in Pulmonary Medicine, 2019, 25, 354-361.	2.6	12
138	Summary for Clinicians: Clinical Practice Guideline for Management of Malignant Pleural Effusions. Annals of the American Thoracic Society, 2019, 16, 17-21.	3.2	12
139	Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. OncoImmunology, 2020, 9, 1684713.	4.6	12
140	Alteplase Dose Assessment for Pleural infection Therapy (<scp>ADAPT</scp>) Studyâ€: Use of 2.5Âmg alteplase as a starting intrapleural dose. Respirology, 2022, 27, 510-516.	2.3	12
141	Pleurodesis: A novel experimental model. Respirology, 2007, 12, 500-504.	2.3	11
142	Use of endobronchial one-way valves reveals questions on etiology of spontaneous pneumothorax: report of three cases. Journal of Cardiothoracic Surgery, 2009, 4, 63.	1.1	11
143	Malignant Pleural Effusions. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 3-5.	5.6	10
144	A rapid, LC-MS/MS assay for quantification of piperacillin and tazobactam in human plasma and pleural fluid; application to a clinical pharmacokinetic study. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1081-1082, 58-66.	2.3	10

#	Article	IF	Citations
145	The feasibility of a pragmatic distance-based intervention to increase physical activity in lung cancer survivors. European Journal of Cancer Care, 2018, 27, e12722.	1.5	10
146	Very lowâ€dose intrapleural tPA for indwelling pleural catheterâ€associated symptomatic fluid loculation. Respirology Case Reports, 2019, 7, e00457.	0.6	10
147	Successful management of pleural infection with very low dose intrapleural tissue plasminogen activator/deoxyribonuclease regime. Respirology Case Reports, 2019, 7, e00408.	0.6	10
148	Clinically Significant Pleural Effusion in Intensive Care: A Prospective Multicenter Cohort Study. , 2020, 2, e0070.		10
149	Bacterial Infection Elicits Heat Shock Protein 72 Release from Pleural Mesothelial Cells. PLoS ONE, 2013, 8, e63873.	2.5	10
150	Hunting for a pleural fluid test for mesothelioma: is soluble mesothelin the answer?. Thorax, 2007, 62, 561-562.	5.6	9
151	A distinctive colour associated with high iodine content in malignant pleural effusion from metastatic papillary thyroid cancer: a case report. Journal of Medical Case Reports, 2013, 7, 147.	0.8	9
152	Mouse models of mesothelioma: strengths, limitations and clinical translation. Lung Cancer Management, 2014, 3, 397-410.	1.5	9
153	Simplified Criteria Using Pleural Fluid Cholesterol and Lactate Dehydrogenase to Distinguish between Exudative and Transudative Pleural Effusions. Respiration, 2019, 98, 48-54.	2.6	9
154	Pleural effusions and pneumothorax: Beyond simple plumbing. Respirology, 2020, 25, 963-971.	2.3	9
155	Role of early definitive management for newly diagnosed malignant pleural effusion related to lung cancer. Respirology, 2020, 25, 1167-1173.	2.3	9
156	Intrapleural Fibrinolytics and Deoxyribonuclease for Treatment of Indwelling Pleural Catheter-Related Pleural Infection: A Multi-Center Observational Study. Respiration, 2021, 100, 452-460.	2.6	9
157	Diagnosis of pleural infection: state-of-the-art. Current Respiratory Care Reports, 2012, 1, 101-110.	0.6	8
158	Two sequential tPA/DNase courses for noncommunicating loculated collections in pleural infection. Respirology Case Reports, 2014, 2, 87-89.	0.6	8
159	Emerging concepts in pleural infection. Current Opinion in Pulmonary Medicine, 2018, 24, 367-373.	2.6	8
160	Air in the Pleural Cavity Enhances Detection of Pleural Abnormalities by CT Scan. Chest, 2018, 153, e123-e128.	0.8	8
161	Steroid Therapy and Outcome of Parapneumonic Pleural Effusions (STOPPE): A Pilot Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1093-1101.	5.6	8
162	Mesothelial cells activate the plasma kallikrein-kinin system during pleural inflammation. Biological Chemistry, 2011, 392, 633-42.	2.5	7

#	Article	IF	Citations
163	Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors. BMC Research Notes, 2018, 11, 864.	1.4	7
164	Pleural empyema in a patient with a perinephric abscess and diaphragmatic defect. Respirology Case Reports, 2019, 7, e00400.	0.6	7
165	Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1â€3 tyrosine kinase inhibitor anticancer therapy. Clinical and Experimental Ophthalmology, 2021, 49, 579-590.	2.6	7
166	PPARÎ± and PPARÎ³ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective. IScience, 2022, 25, 103571.	4.1	7
167	Pseudo-tumor Mimicking Indwelling Pleural Catheter Tract Metastasis in Mesothelioma. Journal of Bronchology and Interventional Pulmonology, 2014, 21, 350-352.	1.4	6
168	Histopathology of removed indwelling pleural catheters from patients with malignant pleural diseases. Respirology, 2016, 21, 939-942.	2.3	6
169	Blood Patch for Pneumothorax: a Literature Review. Current Pulmonology Reports, 2017, 6, 30-38.	1.3	6
170	Streptococcus pneumoniae potently induces cell death in mesothelial cells. PLoS ONE, 2018, 13, e0201530.	2.5	6
171	Pleural fluid lactate as a point-of-care adjunct diagnostic aid to distinguish tuberculous and complicated parapneumonic pleural effusions during initial thoracentesis: Potential use in a tuberculosis endemic setting. Respiratory Investigation, 2020, 58, 367-375.	1.8	6
172	Pneumothorax, Chylothorax, Hemothorax, and Fibrothorax. , 2010, , 1764-1791.		6
173	An international survey on the use of intrapleural tPA/DNase therapy for pleural infection. ERJ Open Research, 2022, 8, 00590-2021.	2.6	6
174	A Pleural Effusion of Multiple Causes. Chest, 2012, 141, 1094-1097.	0.8	5
175	Nutrition, exercise, and complementary medicine: potential role in mesothelioma?. Current Pulmonology Reports, 2016, 5, 20-27.	1.3	5
176	Pleural infection: <scp>T</scp>o drain or not to drain?. Respirology, 2017, 22, 1055-1056.	2.3	5
177	Malignant pleural mesothelioma presenting with remittingâ€“relapsing pleural effusions: report of two cases. Respirology Case Reports, 2018, 6, e00306.	0.6	5
178	Pathogenesis of pleural infection: <scp>A</scp> complex warfare. Respirology, 2018, 23, 8-9.	2.3	5
179	Changes in body composition in patients with malignant pleural mesothelioma and the relationship with activity levels and dietary intake. European Journal of Clinical Nutrition, 2022, 76, 979-986.	2.9	5
180	Pneumothorax: Clearing the Air on the Pressure-Dependent Airleak Hypothesis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 143-144.	5.6	5

#	Article	IF	Citations
181	Ipsilateral and contralateral hemidiaphragm dynamics in symptomatic pleural effusion: The 2nd <scp>PLeural</scp> Effusion And Symptom Evaluation (<scp>PLEASE</scp>â€2) Study. Respirology, 2022, 27, 882-889.	2.3	5
182	Impact Factor and Its Role in Academic Promotion. Respirology, 2009, 14, 914-914.	2.3	4
183	Unintentional intramuscular administration of tPA / DN ase for pleural infection. Respirology Case Reports, 2014, 2, 144-146.	0.6	4
184	Preclinical Assessment of Adjunctive tPA and DNase for Peritoneal Dialysis Associated Peritonitis. PLoS ONE, 2015, 10, e0119238.	2.5	4
185	A massive pleuralâ€based desmoid tumour. Respirology Case Reports, 2017, 5, e00205.	0.6	4
186	Pleural Biopsy to Capture Causative Microbe. Chest, 2018, 154, 743-745.	0.8	4
187	Malignant Pleural Mesothelioma: an Update for Pulmonologists. Current Pulmonology Reports, 2019, 8, 40-49.	1.3	4
188	Expanding knowledge on nonâ€expandable lungs. Respirology, 2020, 25, 238-239.	2.3	4
189	Key Highlights From the American Association for Bronchology and Interventional Pulmonology Evidence-Informed Guidelines and Expert Panel Report for the Management of Indwelling Pleural Catheters. Chest, 2021, 159, 920-923.	0.8	4
190	Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance. PLoS ONE, 2021, 16, e0250628.	2.5	4
191	The continual search for ideal biomarkers for mesothelioma: the hurdles. Journal of Thoracic Disease, 2013, 5, 364-6.	1.4	4
192	Malignant Pleural Mesothelioma. Clinics in Chest Medicine, 2021, 42, 697-710.	2.1	4
193	Australasian Malignant PLeural Effusion (AMPLE)-3 trial: study protocol for a multi-centre randomised study comparing indwelling pleural catheter (Â±talc pleurodesis) versus video-assisted thoracoscopic surgery for management of malignant pleural effusion. Trials, 2022, 23, .	1.6	4
194	Asbestosâ€related pleural disease in Western Australian goldâ€miners. Medical Journal of Australia, 1999, 170, 263-265.	1.7	3
195	Pleural fluid exchange in rabbits. Respirology, 2007, 12, 495-499.	2.3	3
196	How to write research papers and grants: 2011 Asian Pacific Society for Respirology Annual Scientific Meeting Postgraduate Session. Respirology, 2012, 17, 792-801.	2.3	3
197	Diagnoses (Not Diagnosis) of Pleural Effusion. Time to Consider Concurrent Etiologies. Annals of the American Thoracic Society, 2016, 13, 1003-1004.	3.2	3
198	Corticosteroids in Lung and Pleural Infections. Current Pulmonology Reports, 2018, 7, 19-27.	1.3	3

#	Article	IF	Citations
199	Osler Centenary Papers: Management of pleural infection: Oslerâ€™s final illness and recent advances. Postgraduate Medical Journal, 2019, 95, 656-659.	1.8	3
200	Twentyâ€five years of Respirology: Advances in pleural disease. Respirology, 2020, 25, 38-40.	2.3	3
201	suPAR Surprises as a Biomarker of Invasive Outcomes in Pleural Infection. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1470-1472.	5.6	3
202	Hyaluronic acid in viscous malignant mesothelioma pleural effusion. Respirology Case Reports, 2021, 9, e00694.	0.6	3
203	Conservative management of a complete primary spontaneous pneumothorax. Respirology Case Reports, 2021, 9, e0837.	0.6	3
204	Management of primary spontaneous pneumothorax: less is more. Lancet, The, 2020, 396, 1973.	13.7	3
205	A year in review: Respirology 2005 - Clinical science. Respirology, 2006, 11, 124-130.	2.3	2
206	Pleural Effusion, Empyema, and Pneumothorax. , 2008, , 853-867.		2
207	Reproducibility and reliability of pleural fluid cytokine measurements. European Respiratory Journal, 2009, 34, 1001-1003.	6.7	2
208	The need for translational research in respiratory medicine. Translational Respiratory Medicine, 2013, 1, 9.	3.8	2
209	Pleural empyema caused by <scp>K</scp>lebsiella oxytoca: A case series. Respirology, 2015, 20, 507-509.	2.3	2
210	Pleurodesis and systemic inflammatory markers: Lessons and insights. Respirology, 2020, 25, 676-677.	2.3	2
211	Longâ€term followâ€up after intrapleural <scp>tPA</scp>/<scp>DNase</scp> therapy for pleural infection. Respirology, 2021, 26, 388-391.	2.3	2
212	The pathophysiology of breathlessness and other symptoms associated with pleural effusions. , 2020, , 13-28.		2
213	Coulter Counter Registers Talc Particles as Leukocytes. Chest, 2001, 119, 669-670.	0.8	2
214	Respirology year-in-review 2006: Clinical science. Respirology, 2007, 12, 6-15.	2.3	1
215	Respirology: To unpathed waters and undreamed shores. Respirology, 2009, 14, 622-622.	2.3	1
216	Pleural Effusion, Empyema, and Pneumothorax. , 2012, , 818-836.		1

#	Article	IF	Citations
217	<scp>H</scp> enochâ€“ <scp>S</scp> chonlein purpura in mesothelioma. Respirology Case Reports, 2014, 2, 138-140.	0.6	1
218	Pleural Infections in Intensive Care. Chest, 2016, 150, 1419-1420.	0.8	1
219	Reply: â€œLess Is Moreâ€•Approach for Management of Intrapleural Sepsis. Annals of the American Thoracic Society, 2017, 14, 1356-1357.	3.2	1
220	Treatment Approaches for Malignant Pleural Effusion. JAMA - Journal of the American Medical Association, 2018, 319, 1507.	7.4	1
221	Predicting Patient Outcome in the Evolving Field of Malignant Pleural Effusion. Journal of Bronchology and Interventional Pulmonology, 2020, 27, 1-3.	1.4	1
222	Pleural Anatomy and Fluid Analysis. , 2013, , 545-555.		1
223	Could Decortication Become Necessary in Cases of Pseudochylothorax?: Response. Chest, 2010, 138, 1023-1024.	0.8	0
224	Respirology: A thank you note from the outgoing editor. Respirology, 2011, 16, 1017-1017.	2.3	0
225	Complications of Removal of Indwelling Pleural Catheters: Response. Chest, 2012, 142, 1071-1072.	0.8	0
226	Response. Chest, 2014, 146, e111-e112.	0.8	0
227	Response. Chest, 2015, 147, e233.	0.8	0
228	Reply. Respirology, 2015, 20, 170-171.	2.3	0
229	Bronchopleural communication following intrapleural doses of tPA / DNase for empyema. Respirology Case Reports, 2020, 8, e00646.	0.6	0
230	Widespread pulmonary invasion by malignant pleural mesothelioma: an important diagnostic consideration. Respirology Case Reports, 2020, 8, e00675.	0.6	0
231	Endomicroscopy of the pleura highlights challenges and limitations of pleuroscopy. Respirology, 2021, 26, 138-139.	2.3	0
232	Trace element levels in pleural effusions. Health Science Reports, 2021, 4, e262.	1.5	0
233	Protocol for a pilot feasibility, safety and efficacy study of artificially introducing an air-pleura interface for detection of pleural nodules by computed tomography: the AIR study. Medicine, Case Reports and Study Protocols, 2021, 2, e0123.	0.1	0
234	Pleural Effusion: Hemothorax. , 2022, , 445-455.		0

#	Article	IF	Citations
235	Rare Pleural Diseases. , 2022, , 515-527.		0
236	Pleural Infection. , 2022, , 243-258.		0
237	Bedside ultrasonography to determine pleurodesis success: SIMPLE but how sound?. Lancet Respiratory Medicine,the, 2021, , .	10.7	0
238	Clump material within drainage chest tubes contains diagnostic information: a proof-of-concept case series. European Respiratory Journal, 2021, 57, 2003248.	6.7	0
239	Ultrasound Clues in Lobar Pneumonia. Chest, 2022, 161, e59-e62.	0.8	0